שווי פעילות לרווח לפני ריבית, מסים ופחת 60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals focuses on malaria therapies for military and traveler needs. This price chart reflects an EV/EBITDA ratio of 0.00. Current revenue is based on Pentagon government contracts, although the growth potential for new drugs is still emerging. Meanwhile, the business possesses immense scalability potential: a single successful drug could generate colossal profits with low production costs.

This indicator determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA multiple chart, an investor assesses the efficiency of capital management and debt load. For 60 Degrees Pharmaceuticals (SXTP), this metric reflects the capital intensity of developing unique antimalarial drugs, converting regulatory approval into actual market asset value.